<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink">        <front>        <journal-meta>            <journal-id journal-id-type="nlm-ta">elife</journal-id>            <journal-id journal-id-type="publisher-id">eLife</journal-id>            <journal-title-group>                <journal-title>eLife</journal-title>            </journal-title-group>            <issn publication-format="electronic">2050-084X</issn>            <publisher>                <publisher-name>eLife Sciences Publications, Ltd</publisher-name>            </publisher>        </journal-meta>        <article-meta>            <article-id pub-id-type="publisher-id">71156</article-id>            <article-id pub-id-type="doi">10.7554/eLife.71156</article-id>            <article-categories>                <subj-group subj-group-type="display-channel">                    <subject>Research Article</subject>                </subj-group>                <subj-group subj-group-type="heading">                    <subject>Medicine</subject>                </subj-group>            </article-categories>            <title-group>                <article-title>A novel immunopeptidomic-based pipeline for the generation of                    personalized oncolytic cancer vaccines</article-title>            </title-group>            <contrib-group>                <contrib contrib-type="author" id="author-241816">                    <name>                        <surname>Feola</surname>                        <given-names>Sara</given-names>                    </name>                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4012-4310</contrib-id>                    <xref ref-type="aff" rid="aff1">1</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-241817">                    <name>                        <surname>Chiaro</surname>                        <given-names>Jacopo</given-names>                    </name>                    <xref ref-type="aff" rid="aff1">1</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-241818">                    <name>                        <surname>Martins</surname>                        <given-names>Beatriz</given-names>                    </name>                    <xref ref-type="aff" rid="aff1">1</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-241819">                    <name>                        <surname>Russo</surname>                        <given-names>Salvatore</given-names>                    </name>                    <xref ref-type="aff" rid="aff1">1</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-184993">                    <name>                        <surname>Fusciello</surname>                        <given-names>Manlio</given-names>                    </name>                    <xref ref-type="aff" rid="aff1">1</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-180803">                    <name>                        <surname>Ylösmäki</surname>                        <given-names>Erkko</given-names>                    </name>                    <xref ref-type="aff" rid="aff1">1</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-245139">                    <name>                        <surname>Bonini</surname>                        <given-names>Chiara</given-names>                    </name>                    <xref ref-type="aff" rid="aff2">2</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-273676">                    <name>                        <surname>Ruggiero</surname>                        <given-names>Eliana</given-names>                    </name>                    <xref ref-type="aff" rid="aff2">2</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-241820">                    <name>                        <surname>Hamdan</surname>                        <given-names>Firas</given-names>                    </name>                    <xref ref-type="aff" rid="aff1">1</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-241821">                    <name>                        <surname>Feodoroff</surname>                        <given-names>Michaela</given-names>                    </name>                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6094-9838</contrib-id>                    <xref ref-type="aff" rid="aff1">1</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-241822">                    <name>                        <surname>Antignani</surname>                        <given-names>Gabriella</given-names>                    </name>                    <xref ref-type="aff" rid="aff1">1</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-101871">                    <name>                        <surname>Viitala</surname>                        <given-names>Tapani</given-names>                    </name>                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9074-9450</contrib-id>                    <xref ref-type="aff" rid="aff3">3</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-241823">                    <name>                        <surname>Pesonen</surname>                        <given-names>Sari</given-names>                    </name>                    <xref ref-type="aff" rid="aff4">4</xref>                    <xref ref-type="fn" rid="conf2"/>                </contrib>                <contrib contrib-type="author" id="author-273675">                    <name>                        <surname>Grönholm</surname>                        <given-names>Mikaela</given-names>                    </name>                    <xref ref-type="aff" rid="aff1">1</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-241825">                    <name>                        <surname>Branca</surname>                        <given-names>Rui MM</given-names>                    </name>                    <xref ref-type="aff" rid="aff5">5</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" id="author-120062">                    <name>                        <surname>Lehtiö</surname>                        <given-names>Janne</given-names>                    </name>                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8100-9562</contrib-id>                    <xref ref-type="aff" rid="aff6">6</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <contrib contrib-type="author" corresp="yes" id="author-154970">                    <name>                        <surname>Cerullo</surname>                        <given-names>Vincenzo</given-names>                    </name>                    <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4901-3796</contrib-id>                    <xref ref-type="aff" rid="aff7">7</xref>                    <xref ref-type="corresp" rid="cor1">*</xref>                    <xref ref-type="fn" rid="conf1"/>                </contrib>                <aff id="aff1"><institution content-type="dept">Drug Research Program (DRP)                        ImmunoViroTherapy Lab</institution>, <institution>University of                        Helsinki</institution>, <addr-line><named-content content-type="city">Helsinki</named-content></addr-line>, <country>Finland</country></aff>                <aff id="aff2"><institution content-type="dept">Experimental Hematology                        Unit</institution>, <institution>University Vita e Salute San                        Raffaele</institution>, <addr-line><named-content content-type="city">Milan</named-content></addr-line>, <country>Italy</country></aff>                <aff id="aff3"><institution content-type="dept">Pharmaceutical Biophysics Research                        Group</institution>, <institution>University of Helsinki</institution>,                            <addr-line><named-content content-type="city">Helsinki</named-content></addr-line>, <country>Finland</country></aff>                <aff id="aff4"><institution>Valo Therapeutics Oy</institution>,                            <addr-line><named-content content-type="city">Helsinki</named-content></addr-line>, <country>Finland</country></aff>                <aff id="aff5"><institution content-type="dept">Department of                        Oncology-Pathology</institution>, <institution>Karolinska                        Institutet</institution>, <addr-line><named-content content-type="city">stockholm</named-content></addr-line>, <country>Sweden</country></aff>                <aff id="aff6"><institution content-type="dept">Department of                        Oncology-Pathology</institution>, <institution>Karolinska                        Institute</institution>, <addr-line><named-content content-type="city">Stockholm</named-content></addr-line>, <country>Sweden</country></aff>                <aff id="aff7"><institution content-type="dept">ImmunoVirothearpy Lab, Faculty of                        Pharmacy</institution>, <institution>University of Helsinki</institution>,                            <addr-line><named-content content-type="city">Helsinki</named-content></addr-line>, <country>Finland</country></aff>            </contrib-group>            <contrib-group content-type="section">                <contrib contrib-type="editor" id="author-179857">                    <name>                        <surname>Ho</surname>                        <given-names>Ping-Chih</given-names>                    </name>                    <role>Reviewing editor</role>                    <aff><institution>Ludwig Institute for Cancer Research</institution>,                            <country>Switzerland</country></aff>                </contrib>            </contrib-group>            <author-notes>                <corresp id="cor1"><label>*</label>For correspondence:                        <email>vincenzo.cerullo@helsinki.fi</email> (VC);</corresp>            </author-notes>            <pub-date date-type="pub" publication-format="electronic">                <day>22</day>                <month>03</month>                <year>2022</year>            </pub-date>            <volume>11</volume>            <elocation-id>e71156</elocation-id>            <history><date date-type="received">                    <day>11</day>                    <month>06</month>                    <year>2021</year>                </date><date date-type="accepted">                    <day>01</day>                    <month>03</month>                    <year>2022</year>                </date></history>            <permissions>                <copyright-statement>© 2022, Feola et al</copyright-statement>                <copyright-year>2022</copyright-year>                <copyright-holder>Feola et al</copyright-holder>                <license xlink:href="http://creativecommons.org/licenses/by/4.0/">                    <license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative                            Commons Attribution License</ext-link> permitting unrestricted use and                        redistribution provided that the original author and source are                        credited.</license-p>                </license>            </permissions>            <self-uri content-type="pdf" xlink:href="elife-71156-v1.pdf"/><abstract>                <p>Beside the isolation and identification of MHC-I restricted peptides from the                    surface of cancer cells, one of the challenges is eliciting an effective                    anti-tumor CD8+ T cell mediated response as part of therapeutic cancer vaccine.                    Therefore, the establishment of a solid pipeline for the downstream selection of                    clinically relevant peptides and the subsequent creation of therapeutic cancer                    vaccines are of utmost importance. Indeed, the use of peptides for eliciting                    specific anti-tumor adaptive immunity is hindered by two main limitations: the                    efficient selection of the most optimal candidate peptides and the use of a                    highly immunogenic platform to combine with the peptides to induce effective                    tumor-specific adaptive immune responses. Here, we describe for the first time a                    streamlined pipeline for the generation of personalized cancer vaccines starting                    from the isolation and selection of the most immunogenic peptide candidates                    expressed on the tumor cells and ending in the generation of efficient                    therapeutic oncolytic cancer vaccines. This immunopeptidomics-based pipeline was                    carefully validated in a murine colon tumor model CT26. Specifically, we used                    state-of-the-art immunoprecipitation and mass spectrometric methodologies to                    isolate &gt;8000 peptide targets from the CT26 tumor cell line. The selection of                    the target candidates was then based on two separate approaches: RNAseq analysis                    and the HEX software. The latter is a tool previously developed by Chiaro et al.                    (1), able to identify tumor antigens similar to pathogen antigens, in order to                    exploit molecular mimicry and tumor pathogen cross-reactive T-cells in cancer                    vaccine development. The generated list of candidates (twenty-six in total) was                    further tested in a functional characterization assay using interferon-g ELISpot                    (Enzyme-Linked Immunospot), reducing the number of candidates to six. These                    peptides were then tested in our previously described oncolytic cancer vaccine                    platform PeptiCRAd, a vaccine platform that combines an immunogenic oncolytic                    adenovirus (OAd) coated with tumor antigen peptides. In our work, PeptiCRAd was                    successfully used for the treatment of mice bearing CT26, controlling the                    primary malignant lesion and most importantly a secondary, non-treated, cancer                    lesion. These results confirmed the feasibility of applying the described                    pipeline for the selection of peptide candidates and generation of therapeutic                    oncolytic cancer vaccine, filling a gap in the field of cancer immunotherapy,                    and paving the way to translate our pipeline into human therapeutic                    approach.</p>            </abstract>            <kwd-group kwd-group-type="research-organism">                <title>Research organism</title>                <kwd>Mouse</kwd>            </kwd-group>            <funding-group>                <funding-statement>The funders had no role in study design, data collection and                    interpretation, or the decision to submit the work for                    publication.</funding-statement>            </funding-group>        </article-meta>    </front>    <back>        <sec id="s1" sec-type="additional-information">            <title>Additional information</title>            <fn-group content-type="competing-interest">                <title>Competing interest</title>                <fn fn-type="conflict" id="conf2">                    <p>Sari Pesonen, is an employee and a shareholder at VALO Therapeutics.</p>                </fn>                <fn fn-type="conflict" id="conf1">                    <p>The other authors declare that no competing interests exist.</p>                </fn>            </fn-group>            <fn-group content-type="ethics-information">                <title>Ethics</title>                <fn fn-type="other">                    <p>Animal experimentation: All animal experiments were reviewed and approved by                        the Experimental Animal Committee of the University of Helsinki and the                        Provincial Government of Southern Finland (license number                        ESAVI/11895/2019).4-6 weeks old female Balb/cOlaHsd mice were obtained from                        Envigo (Laboratory, Bar Harbor, Maine UK).</p>                </fn>            </fn-group>        </sec>        <sec id="s2" sec-type="supplementary-material">            <title>Additional Files</title>            <sec id="s3" sec-type="data-availability">                <title>Data availability</title>                <p>The mass spectrometry proteomics data have been deposited to the ProteomeXchange                    Consortium via the PRIDE partner repository with the dataset identifier                    PXD026463. The ligandome dataset is currently hidden but will be made public                    upon eventual acceptance of the current manuscript.Reviewer Account details for                    ligandome data accessing: https://www.ebi.ac.uk/pride/login PXD026463Username:                    reviewer_pxd026463@ebi.ac.ukPassword: oMUWIAw3</p>                <p>The following datasets were generated:</p>                <p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy">                        <person-group person-group-type="author"><collab>Sara                                Feola</collab><collab>Jacopo Chiaro</collab><collab>Beatriz                                Martins</collab><collab>Salvatore Russo</collab><collab>Manlio                                Fusciello</collab><collab>Erkko Ylösmäki</collab><collab>Firas                                Hamdan</collab><collab>Michaela Feodoroff et                            al.</collab></person-group>                        <year iso-8601-date="2021">2021</year>                        <source>A novel immunopeptidomic-based pipeline for the generation of                            personalized oncolytic cancer vaccines</source>                        <ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/pride/login">https://www.ebi.ac.uk/pride/login</ext-link>                        <comment>Pride, PXD026463</comment>                    </element-citation></p>                <p>The following previously published datasets were used:</p>                <p><element-citation id="dataset2" publication-type="data" specific-use="references">                        <person-group person-group-type="author"><collab>Laumont                                CM</collab><collab>Vincent K</collab><collab>Hesnard                                L</collab><collab>Audemard E</collab><collab>Bonneil                                E</collab><collab>Laverdure JP</collab></person-group>                        <year iso-8601-date="2018">2018</year>                        <source>Noncoding regions are the main source of targetable tumor-specific                            antigens</source>                        <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111092">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE111092</ext-link>                        <comment>NCBI Gene Expression Omnibus, GSE111092</comment>                    </element-citation><element-citation id="dataset3" publication-type="data" specific-use="references">                        <person-group person-group-type="author"><collab>Proquin                                H</collab><collab>Jetten MJ</collab><collab>Jonkhout                                MCM</collab><collab>Garduño-Balderas LG et                            al.</collab></person-group>                        <year iso-8601-date="2018">2018</year>                        <source>Transcriptomics effects of ingestion of food additive titanium                            dioxide (E171) in the colon of BALB/c mice</source>                        <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92563">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE92563</ext-link>                        <comment>NCBI Gene Expression Omnibus,GSE92563</comment>                    </element-citation><element-citation id="dataset4" publication-type="data" specific-use="references">                        <person-group person-group-type="author"><collab>Laumont                                CM</collab><collab>Vincent K</collab><collab>Hesnard                                L</collab><collab>Audemard E</collab><collab>Bonneil                                E</collab><collab>Laverdure JP</collab></person-group>                        <year iso-8601-date="2018">2018</year>                        <source>Noncoding regions are the main source of targetable tumor-specific                            antigens</source>                        <ext-link ext-link-type="uri" xlink:href="https://stm.sciencemag.org/content/suppl/2018/12/03/10.470.eaau5516.DC1">https://stm.sciencemag.org/content/suppl/2018/12/03/10.470.eaau5516.DC1</ext-link>                        <comment>Table S3</comment>                    </element-citation></p>            </sec>        <supplementary-material><ext-link xlink:href="elife-71156-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec>    </back></article>